Brain scan study in treatment-resistant depression
Part of Mental health clinical trials.
This study compares brain synaptic density in people with treatment-resistant depression, people with depression that responds to treatment, and healthy controls. It uses a PET scan to measure synaptic density and aims to understand the biological differences.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 25 and 65 years old.
- You must be able to undergo an MRI scan (no metal implants, pacemaker, etc.).
- You must not be pregnant or nursing.
- If you are in the depression group, you must meet criteria for major depressive disorder and have moderate to severe symptoms.
- If you are in the depression group, you must not have taken certain psychiatric medications recently (except for some antidepressants).
- If you are a healthy control, you must have no history of psychiatric disorders or antidepressant use.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the brain's frontal lobe (DLPFC) works during memory tasks in people with treatment-resistant depression. It compares brain activity between depressed patients and healthy controls using MRI and possibly a brain stimulation technique (rTMS). It aims to understand why some people don't respond to standard treatments.
This trial tests whether using brain-related “biomarkers” from your scans to guide rTMS can improve depression that hasn’t responded to at least one antidepressant. It may help by targeting brain circuits linked to depression more precisely.
This trial uses PET scans to see how transcranial magnetic stimulation (TMS) affects the brain in people whose depression hasn't improved with at least two different antidepressants. It aims to find markers that could predict who might benefit from TMS.
This trial looks at how people with treatment-resistant major depression respond when starting a new depression medicine that affects glutamate signaling. It also involves brain scans and thinking/learning tasks, aiming to understand what helps people improve when standard treatments haven’t worked.
This trial tests an alternating combination of brain stimulation and brain imaging to see if it helps people with depression that hasn’t improved with usual treatments. The goal is to find a safer, more effective approach for people whose depression has been very difficult to treat.
This trial uses two special brain scans (DPA-714 and FDG PET/MRI) to look at inflammation and brain activity in people with first-episode or recurrent depression, and in healthy volunteers. It aims to find brain differences that could lead to better treatments.
Hear when a new Treatment Resistant Depression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.